Effect of long-term treatment with GLP-1RA on cardiovascular outcomes in patients with type 2 diabetes mellitus: an ambispective cohort study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300073001

Enrollment

Unknown

Registered

2023-06-29

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM

Interventions

Experimental group (polyethylene glycol loxenatide):None

Control group (non-incretin anti-diabetic drugs):None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Type 2 diabetes mellitus;2.Treatment with polyethylene glycol loxenatide or non-incretin anti-diabetic drugs for more than 6 months;3.Participants who met at least one of the cardiovascular disease criteria or one cardiovascular risk factor.

Exclusion criteria

Exclusion criteria: Patients with type 2 diabetes who have been hospitalized due to COVID-19.

Design outcomes

Primary

Measure	Time frame
3-point major adverse cardiac event comprises of cardiovascular (CV) death, nonfatal myocardial infarction (MI) or nonfatal stroke;	—

Secondary

Measure	Time frame
Expanded MACE. Defined as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke,coronary revascularization or hospitalization for unstable angina;HbA1c;Body Weight;	—

Countries

China

Contacts

Public ContactLi Jilin

Second Affiliated Hospital of Shantou University Medical College

lijilin@126.com+86 135 9285 2807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026